Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKSUOI)

• Drug Name: Flavopiridol Drug Info
• Synonyms: FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2	[1]
Chronic lymphocytic leukaemia	2A82.0	Discontinued in Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 5287969
  ChEBI ID: CHEBI:47344
  CAS Number: CAS 146426-40-6
  TTD Drug ID: DMKSUOI
  VARIDT Drug ID: DR00235
  INTEDE Drug ID: DR0079

Molecule-Related Drug Atlas

Drug(s) Targeting Cyclin-dependent kinase 9 (CDK9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[15]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[16]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
BTX-A51	DMC8XHQ	Advanced solid tumour	2A00-2F9Z	Phase 1	[18]
CYC065	DM9ODT6	Lymphoma	2A80-2A86	Phase 1	[4]
AZD4573	DMOYPTK	Haematological malignancy	2B33.Y	Phase 1	[4]
TP-1287	DM3Z07E	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
VIP-152	DMBQ5OL	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[20]
AZD7503	DM8XJD2	Non-alcoholic steatohepatitis	DB92.1	Phase 1	[21]
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[22]

Drug(s) Targeting Cyclin-dependent kinase (CDK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[23]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[4]
PF-06873600	DMRZHV6	Breast cancer	2C60-2C65	Phase 1	[4]
PMID26161698-Compound-44	DM8UPO3	N. A.	N. A.	Patented	[22]
Purine derivative 4	DMYD5SQ	N. A.	N. A.	Patented	[22]
Indole-based analog 12	DM1CNRH	N. A.	N. A.	Patented	[22]
PMID26161698-Compound-10	DMXVCHZ	N. A.	N. A.	Patented	[22]
BS-194	DMLXFHD	Solid tumour/cancer	2A00-2F9Z	Investigative	[24]

Drug(s) Targeting Myophosphorylase (PYGM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PSN357	DMDOFE7	Type-2 diabetes	5A11	Discontinued in Phase 2	[25]
GSK-1362885	DMBXYKG	Type-2 diabetes	5A11	Discontinued in Phase 1	[26]

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[27]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[28]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[29]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[30]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[31]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[32]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[33]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[34]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[35]

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[36]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[6]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[37]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[38]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[37]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[39]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[40]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[41]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[42]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[39]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[43]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[44]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[45]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[46]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[47]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[48]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[49]
Metronidazole	DMTIVEN	Abscess		Approved	[7]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[50]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[51]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[52]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[55]
Vismodegib	DM5IXKQ	Basal cell carcinoma	2C32	Approved	[56]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[57]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[58]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[59]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[60]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[62]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[63]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[64]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[65]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[66]
Selenium	DM25CGV	N. A.	N. A.	Approved	[67]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[62]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[68]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[68]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[70]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[71]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[72]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[73]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[74]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[75]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[76]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[77]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[78]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[79]

Drug(s) Affected By CASP8 and FADD-like apoptosis regulator (CFLAR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[80]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[81]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[82]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[83]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[84]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[85]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[79]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[86]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[87]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[88]

Drug(s) Affected By Serine protease HTRA2, mitochondrial (HTRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[89]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[90]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[91]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[92]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[93]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[94]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[95]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[96]
Bortezomib	DMNO38U	Leukemia		Approved	[97]

Drug(s) Affected By Transforming growth factor beta-1 proprotein (TGFB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[98]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[99]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[101]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[103]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[104]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[105]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[106]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[107]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[107]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[109]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[110]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[111]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[112]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[113]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[114]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[115]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[116]

Drug(s) Affected By Retinoblastoma-associated protein (RB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[117]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[118]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[119]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[120]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[121]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[122]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[123]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[124]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[125]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]

Drug(s) Affected By Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[127]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[128]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[70]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[129]
Selenium	DM25CGV	N. A.	N. A.	Approved	[130]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[74]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[131]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[52]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[132]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[133]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[134]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[73]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[136]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[137]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[136]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[138]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[139]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[140]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[141]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[142]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[143]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[144]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[99]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[133]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[145]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[146]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[147]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[148]

Drug(s) Affected By Mast/stem cell growth factor receptor Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[149]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[150]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[151]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[152]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[153]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[154]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[155]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[156]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[157]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[158]

Drug(s) Affected By Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[159]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[160]
Selenium	DM25CGV	N. A.	N. A.	Approved	[130]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[161]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[52]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[162]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[163]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[91]

Drug(s) Affected By Proliferating cell nuclear antigen (PCNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[133]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[164]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[165]
Selenium	DM25CGV	N. A.	N. A.	Approved	[130]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[166]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[167]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[168]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[52]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[132]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[169]

Drug(s) Affected By G2/mitotic-specific cyclin-B1 (CCNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[127]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[128]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[170]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[129]
Selenium	DM25CGV	N. A.	N. A.	Approved	[130]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[74]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[137]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[171]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[75]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[172]

Drug(s) Affected By Histone H2AX (H2AX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[173]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[174]
Selenium	DM25CGV	N. A.	N. A.	Approved	[175]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[176]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[177]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[178]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[179]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[180]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[181]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[182]

Drug(s) Affected By High mobility group protein HMG-I/HMG-Y (HMGA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[121]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[91]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[183]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[184]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[185]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[95]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[186]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[187]
Methamphetamine	DMPM4SK	Anxiety		Approved	[188]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[189]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[190]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[148]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[191]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[192]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[120]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[193]
Selenium	DM25CGV	N. A.	N. A.	Approved	[175]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[194]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[195]

Drug(s) Affected By G1/S-specific cyclin-E1 (CCNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[133]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[196]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[167]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[137]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[123]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[197]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[198]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[199]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[200]

Drug(s) Affected By DNA-directed RNA polymerase II subunit RPB1 (POLR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[175]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[201]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[202]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[203]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[204]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[75]
Deferasirox	DM6ETS0	Beta thalassemia	3A50.2	Approved	[205]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[206]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[95]

Drug(s) Affected By Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[127]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[128]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[196]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[207]
Selenium	DM25CGV	N. A.	N. A.	Approved	[130]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[137]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[208]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[82]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[162]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]

Drug(s) Affected By NF-kappa-B inhibitor alpha (NFKBIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fructose	DM43AN2	Vomiting	MD90	Approved	[99]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[209]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[64]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[210]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[211]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[212]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[213]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[214]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[215]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]

Drug(s) Affected By Retinoblastoma-like protein 1 (RBL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[127]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[216]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[85]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[91]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[217]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[93]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[93]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[218]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[219]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[150]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[170]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[71]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[120]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[220]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[74]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[221]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[137]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[62]

Drug(s) Affected By Signal transducer and activator of transcription 3 (STAT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[99]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[64]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[222]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[223]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[224]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[225]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[69]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[226]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[227]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[228]

Drug(s) Affected By Caspase-3 (CASP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[229]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[230]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[231]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[111]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[232]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[233]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[234]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[235]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[236]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[209]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[118]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[192]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[221]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[237]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[238]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[239]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[240]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[197]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[241]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[242]

Drug(s) Affected By Tumor necrosis factor ligand superfamily member 10 (TNFSF10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[65]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[80]
Selenium	DM25CGV	N. A.	N. A.	Approved	[175]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[243]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[244]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[82]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[245]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[246]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[247]

Drug(s) Affected By Caspase-9 (CASP9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[248]
Mannitol	DMSCDY9	Bronchiectasis	CA24	Approved	[249]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[133]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[146]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[250]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[251]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[73]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[252]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[253]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[254]

Drug(s) Affected By BH3-interacting domain death agonist (BID)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[64]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[73]
Selenium	DM25CGV	N. A.	N. A.	Approved	[67]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[85]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[255]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[152]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[256]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[257]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[258]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]

Drug(s) Affected By Cytochrome c (CYCS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[64]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[259]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[134]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[250]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[260]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[261]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[107]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[262]
Pefloxacin	DM49IGF	Gonococcal urethritis	1A70.0Y	Approved	[263]

Drug(s) Affected By E3 ubiquitin-protein ligase Mdm2 (MDM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[64]
Flucytosine	DM13VTW	Cryptococcal meningitis		Approved	[264]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[264]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[265]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[52]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[266]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[109]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[267]
Amifostine	DM5FL14	Mucositis	CA00	Approved	[268]

Drug(s) Affected By Transcription factor E2F1 (E2F1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[269]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[133]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[196]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[270]
Selenium	DM25CGV	N. A.	N. A.	Approved	[175]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[62]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[123]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[132]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[141]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[209]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[133]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[145]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[80]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[250]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[120]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[121]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[168]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[137]

Drug(s) Affected By Bcl-2-like protein 1 (BCL2L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[114]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[271]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[73]
Selenium	DM25CGV	N. A.	N. A.	Approved	[175]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[272]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[52]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[264]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[84]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[85]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[245]

Drug(s) Affected By Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[147]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[80]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[273]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[82]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[274]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[275]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[276]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[80]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[277]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[88]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 3 (BIRC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[278]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[209]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[151]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[73]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[52]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[255]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[152]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[279]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[280]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[281]

Drug(s) Affected By Caspase-8 (CASP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[282]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[283]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[284]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[64]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[285]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[286]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[73]
Selenium	DM25CGV	N. A.	N. A.	Approved	[175]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[253]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[107]

Drug(s) Affected By BAG family molecular chaperone regulator 1 (BAG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[175]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[287]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[288]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[289]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[290]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[291]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[292]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[293]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[187]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[294]

Drug(s) Affected By Diablo IAP-binding mitochondrial protein (DIABLO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[89]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[165]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[73]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[90]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[275]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[295]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[257]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[296]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[290]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[95]

Drug(s) Affected By Glycogen phosphorylase, brain form (PYGB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[175]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[53]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[288]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[61]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[185]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[95]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[297]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[187]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[298]
Capecitabine	DMTS85L	Adenocarcinoma	2D40	Approved	[299]

Drug(s) Affected By Glycogen phosphorylase, liver form (PYGL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[204]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[300]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[184]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[155]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[301]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[95]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[301]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[297]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[302]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[187]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase (CDK)	TTMBO1Z	NOUNIPROTAC	Inhibitor	[3]
Cyclin-dependent kinase 9 (CDK9)	TT1LVF2	CDK9_HUMAN	Inhibitor	[4]
Myophosphorylase (PYGM)	TT31JXP	PYGM_HUMAN	Inhibitor	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[5]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) Main DME	DEYGVN4	UD11_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[8]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[9]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Gene/Protein Processing	[10]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[10]
BAG family molecular chaperone regulator 1 (BAG1)	OTRQNIA4	BAG1_HUMAN	Gene/Protein Processing	[9]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Gene/Protein Processing	[10]
BH3-interacting domain death agonist (BID)	OTOSHSHU	BID_HUMAN	Protein Interaction/Cellular Processes	[11]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Gene/Protein Processing	[12]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[13]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Protein Interaction/Cellular Processes	[14]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5680).
• [3] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 2012 Sep;11(9):2033-44.
• [6] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [7] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [8] Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther. 2003 Feb;2(2):139-50.
• [9] Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005 Oct 1;106(7):2513-9. doi: 10.1182/blood-2005-04-1678. Epub 2005 Jun 21.
• [10] Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res. 2003 Jan 1;63(1):93-9.
• [11] The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ. 2001 Jul;8(7):715-24. doi: 10.1038/sj.cdd.4400868.
• [12] Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res. 2006 Sep 1;66(17):8858-69. doi: 10.1158/0008-5472.CAN-06-0808.
• [13] Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes. Blood Cells Mol Dis. 2001 May-Jun;27(3):610-24. doi: 10.1006/bcmd.2001.0428.
• [14] Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. J Biol Chem. 2000 Oct 13;275(41):32089-97. doi: 10.1074/jbc.M005267200.
• [15] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [16] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [17] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [18] Clinical pipeline report, company report or official report of BioTheryX.
• [19] Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
• [20] VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.
• [21] ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
• [22] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [23] Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.Clin Cancer Res. 2009 Jun 1;15(11):3716-24.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8176).
• [25] PhRMA
• [26] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [27] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [28] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [29] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [30] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [31] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [32] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [33] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [34] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [35] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [36] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [37] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [38] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [39] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [40] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [41] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [42] FDA Drug Development and Drug Interactions
• [43] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [44] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [45] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [46] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [47] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [48] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [49] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [50] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [51] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [52] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [53] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [54] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [55] Transforming growth factor-beta1 inhibits all-trans retinoic acid-induced apoptosis. Leuk Res. 2006 May;30(5):607-23. doi: 10.1016/j.leukres.2005.09.007. Epub 2005 Oct 19.
• [56] Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One. 2011;6(11):e27306. doi: 10.1371/journal.pone.0027306. Epub 2011 Nov 8.
• [57] Bupropion, an atypical antidepressant, induces endoplasmic reticulum stress and caspase-dependent cytotoxicity in SH-SY5Y cells. Toxicology. 2011 Jul 11;285(1-2):1-7. doi: 10.1016/j.tox.2011.02.006. Epub 2011 Feb 24.
• [58] Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells. Asian Pac J Cancer Prev. 2013;14(11):6469-73. doi: 10.7314/apjcp.2013.14.11.6469.
• [59] Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts. Haematologica. 2006 Mar;91(3):386-9.
• [60] Ouabain induces apoptotic cell death in human prostate DU 145 cancer cells through DNA damage and TRAIL pathways. Environ Toxicol. 2019 Dec;34(12):1329-1339. doi: 10.1002/tox.22834. Epub 2019 Aug 21.
• [61] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [62] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [63] Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. Oncol Rep. 2007 Sep;18(3):523-9.
• [64] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [65] Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation. Neuro Oncol. 2011 Mar;13(3):267-79. doi: 10.1093/neuonc/noq195. Epub 2011 Feb 3.
• [66] Novel functional view of the crocidolite asbestos-treated A549 human lung epithelial transcriptome reveals an intricate network of pathways with opposing functions. BMC Genomics. 2008 Aug 7;9:376.
• [67] Death receptor 5 regulation during selenium-mediated apoptosis in human prostate cancer cells. Cancer Biol Ther. 2002 May-Jun;1(3):287-90. doi: 10.4161/cbt.83.
• [68] Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
• [69] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [70] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [71] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [72] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [73] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [74] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [75] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [76] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [77] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [78] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [79] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
• [80] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [81] PGK1 induction by a hydrogen peroxide treatment is suppressed by antioxidants in human colon carcinoma cells. Biosci Biotechnol Biochem. 2008 Jul;72(7):1799-808. doi: 10.1271/bbb.80079. Epub 2008 Jul 7.
• [82] Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
• [83] Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res. 2001 Feb;7(2):407-14.
• [84] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [85] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [86] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [87] Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol. 2002 Jan;22(1):37-47. doi: 10.1023/a:1014256603539.
• [88] Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Clin Cancer Res. 2012 Dec 15;18(24):6690-701. doi: 10.1158/1078-0432.CCR-12-0770. Epub 2012 Oct 18.
• [89] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [90] Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. Biochim Biophys Acta. 2010 Apr;1803(4):452-67. doi: 10.1016/j.bbamcr.2009.12.005. Epub 2010 Jan 4.
• [91] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [92] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [93] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [94] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [95] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [96] 2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways. Biochem Pharmacol. 2012 Dec 15;84(12):1604-16. doi: 10.1016/j.bcp.2012.09.022. Epub 2012 Oct 5.
• [97] Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res. 2005 Jul 15;65(14):6294-304. doi: 10.1158/0008-5472.CAN-05-0686.
• [98] Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
• [99] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [100] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [101] Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res. 2010 Feb 15;70(4):1314-22. doi: 10.1158/0008-5472.CAN-09-3292. Epub 2010 Feb 9.
• [102] PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells. Antioxid Redox Signal. 2002 Dec;4(6):877-84. doi: 10.1089/152308602762197416.
• [103] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [104] Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol. 2003 Apr;90(4):452-5. doi: 10.1016/S1081-1206(10)61832-7.
• [105] Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol. 2009 Jun;157(3):362-70. doi: 10.1111/j.1476-5381.2009.00161.x. Epub 2009 Apr 9.
• [106] Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy. Dis Colon Rectum. 2001 Jul;44(7):1008-15. doi: 10.1007/BF02235490.
• [107] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [108] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [109] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [110] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [111] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [112] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [113] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [114] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [115] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [116] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [117] Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
• [118] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [119] Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
• [120] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [121] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [122] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [123] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [124] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [125] HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
• [126] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [127] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [128] G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
• [129] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [130] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [131] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [132] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [133] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [134] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [135] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [136] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [137] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [138] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [139] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [140] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [141] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [142] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [143] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [144] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [145] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [146] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [147] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [148] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [149] Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Jan;8(1):152-9. doi: 10.1158/1535-7163.MCT-08-0553.
• [150] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [151] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [152] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [153] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [154] [Demethylation effect of inhibitor As2O3 on expression of SHP-1 and C-kit genes in leukemia HL-60 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):613-6. doi: 10.7534/j.issn.1009-2137.2013.03.015.
• [155] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [156] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [157] Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010 Apr 12;207(4):731-50. doi: 10.1084/jem.20091488. Epub 2010 Apr 5.
• [158] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [159] p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol. 2012 Jul;14(7):870-81. doi: 10.1093/neuonc/nos114. Epub 2012 Jun 18.
• [160] In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells. Food Chem Toxicol. 2022 Jan;159:112722. doi: 10.1016/j.fct.2021.112722. Epub 2021 Dec 3.
• [161] JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 2007 Apr 10;560(2-3):95-100. doi: 10.1016/j.ejphar.2007.01.020. Epub 2007 Jan 19.
• [162] Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010 Nov;26(5):735-41. doi: 10.3892/ijmm_00000520.
• [163] A gene signature-based approach identifies thioridazine as an inhibitor of phosphatidylinositol-3'-kinase (PI3K)/AKT pathway in ovarian cancer cells. Gynecol Oncol. 2011 Jan;120(1):121-7. doi: 10.1016/j.ygyno.2010.10.003. Epub 2010 Oct 29.
• [164] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [165] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [166] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [167] Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation. Toxicol Appl Pharmacol. 2021 Mar 15;415:115450. doi: 10.1016/j.taap.2021.115450. Epub 2021 Feb 9.
• [168] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [169] Epinephrine facilitates the growth of T cell lymphoma by altering cell proliferation, apoptosis, and glucose metabolism. Chem Biol Interact. 2023 Jan 5;369:110278. doi: 10.1016/j.cbi.2022.110278. Epub 2022 Nov 22.
• [170] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [171] Synthesis and antitumor evaluation of nitrovinyl biphenyls: anticancer agents based on allocolchicines. ChemMedChem. 2011 May 2;6(5):859-68. doi: 10.1002/cmdc.201100019. Epub 2011 Apr 6.
• [172] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [173] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
• [174] Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. J Toxicol Sci. 2015 Jun;40(3):329-38. doi: 10.2131/jts.40.329.
• [175] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [176] Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology. 2020 Apr 15;435:152422. doi: 10.1016/j.tox.2020.152422. Epub 2020 Feb 26.
• [177] Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem. 2007 Jul 15;15(14):4863-75. doi: 10.1016/j.bmc.2007.04.057. Epub 2007 May 3.
• [178] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [179] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [180] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
• [181] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [182] The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 Mar 4;3(3):235-44. doi: 10.1016/j.dnarep.2003.10.014.
• [183] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [184] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [185] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [186] NFATc4 mediates ethanol-triggered hepatocyte senescence. Toxicol Lett. 2021 Oct 10;350:10-21. doi: 10.1016/j.toxlet.2021.06.018. Epub 2021 Jun 27.
• [187] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [188] Methamphetamine alters the normal progression by inducing cell cycle arrest in astrocytes. PLoS One. 2014 Oct 7;9(10):e109603.
• [189] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [190] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [191] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [192] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [193] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [194] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [195] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [196] Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res. 2010 Mar;8(3):343-52. doi: 10.1158/1541-7786.MCR-09-0395. Epub 2010 Mar 9.
• [197] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [198] Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur J Pharmacol. 2002 Feb 1;436(1-2):7-13. doi: 10.1016/s0014-2999(01)01577-1.
• [199] Retinoic acid regulates cell cycle progression and cell differentiation in human monocytic THP-1 cells. Exp Cell Res. 2004 Jul 1;297(1):68-81. doi: 10.1016/j.yexcr.2004.02.017.
• [200] [P27(Kip1), cyclin E and endogenous TGF-beta1 changes in apoptosis of NB4 cells induced by As(2)O(3) and/or TGF-beta1 and their significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):74-9.
• [201] Phosphorylation of the RNA polymerase II largest subunit during heat shock and inhibition of transcription in HeLa cells. J Cell Physiol. 1994 Mar;158(3):417-26. doi: 10.1002/jcp.1041580305.
• [202] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [203] Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther. 2014 May;13(5):1142-54.
• [204] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [205] Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology. 2007 Oct 25;367(2):324-33. doi: 10.1016/j.virol.2007.06.011. Epub 2007 Jul 13.
• [206] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [207] Down-regulation and decreased activity of cyclin-dependent kinase 2 in H2O2-induced premature senescence. Int J Biochem Cell Biol. 2003 Feb;35(2):246-54. doi: 10.1016/s1357-2725(02)00129-2.
• [208] Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer. 2003 Dec 10;107(5):844-53. doi: 10.1002/ijc.11446.
• [209] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [210] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [211] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [212] Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem. 2006 Oct;99(2):402-15. doi: 10.1111/j.1471-4159.2006.04005.x.
• [213] Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem. 2001 Dec 21;276(51):47828-33. doi: 10.1074/jbc.M106103200. Epub 2001 Oct 8.
• [214] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [215] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [216] Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130. J Biol Chem. 2003 May 23;278(21):19509-17. doi: 10.1074/jbc.M300511200. Epub 2003 Mar 5.
• [217] Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4). Ann Hematol. 2018 Jan;97(1):83-93. doi: 10.1007/s00277-017-3163-y. Epub 2017 Nov 20.
• [218] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [219] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [220] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [221] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [222] Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
• [223] Diesel exhaust particulate-induced activation of Stat3 requires activities of EGFR and Src in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2007 Feb;292(2):L422-9. doi: 10.1152/ajplung.00204.2006. Epub 2006 Oct 6.
• [224] Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway. Toxicol Appl Pharmacol. 2020 Dec 1;408:115273. doi: 10.1016/j.taap.2020.115273. Epub 2020 Oct 6.
• [225] Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia. 2007 Mar;9(3):192-9. doi: 10.1593/neo.06781.
• [226] Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells. Biocell. 2009 Aug;33(2):107-14.
• [227] Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer. 2011 Jun 16;11:255. doi: 10.1186/1471-2407-11-255.
• [228] Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol. 2014 Feb 1;87(3):424-34. doi: 10.1016/j.bcp.2013.11.008. Epub 2013 Nov 23.
• [229] Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
• [230] [Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Oct;15(5):982-5.
• [231] Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPAR-dependent pathway. Oncotarget. 2016 Mar 1;7(9):10345-62. doi: 10.18632/oncotarget.7213.
• [232] Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
• [233] Induction of mitochondrial manganese superoxide dismutase confers resistance to apoptosis in acute myeloblastic leukaemia cells exposed to etoposide. Br J Haematol. 2000 Mar;108(3):574-81. doi: 10.1046/j.1365-2141.2000.01852.x.
• [234] Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro. Tumour Biol. 2010 Dec;31(6):613-22. doi: 10.1007/s13277-010-0077-x. Epub 2010 Jul 11.
• [235] Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J Cell Physiol. 2000 Jan;182(1):24-32. doi: 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6.
• [236] mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. Biol Chem. 2004 Nov;385(11):1099-103. doi: 10.1515/BC.2004.143.
• [237] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [238] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [239] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [240] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [241] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [242] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [243] Two distinct phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells. J Biol Chem. 2003 May 16;278(20):18092-100. doi: 10.1074/jbc.M300265200. Epub 2003 Mar 13.
• [244] TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. J Pathol. 2011 Feb;223(3):378-89. doi: 10.1002/path.2797. Epub 2010 Oct 29.
• [245] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [246] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [247] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [248] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology. 2003 Sep;144(9):3852-9. doi: 10.1210/en.2003-0098.
• [249] Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J Biol Chem. 2002 Jul 26;277(30):27393-400. doi: 10.1074/jbc.M201963200. Epub 2002 May 14.
• [250] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [251] The effects of quercetin in cultured human RPE cells under oxidative stress and in Ccl2/Cx3cr1 double deficient mice. Exp Eye Res. 2010 Jul;91(1):15-25.
• [252] Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro. J Biochem Mol Toxicol. 2022 Nov;36(11):e23185. doi: 10.1002/jbt.23185. Epub 2022 Aug 3.
• [253] Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer. 2002 Feb 1;86(3):443-8. doi: 10.1038/sj.bjc.6600079.
• [254] Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
• [255] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [256] Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells. Cell Biol Int. 2011 Aug;35(8):803-10. doi: 10.1042/CBI20100739.
• [257] Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G731-8. doi: 10.1152/ajpgi.00150.2005. Epub 2005 Jun 23.
• [258] p38 MAPK/PP2Ac/TTP pathway on the connection of TNF- and caspases activation on hydroquinone-induced apoptosis. Carcinogenesis. 2013 Apr;34(4):818-27. doi: 10.1093/carcin/bgs409. Epub 2013 Jan 3.
• [259] Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol. 2010 May;24(5):969-80. doi: 10.1210/me.2009-0148. Epub 2010 Mar 8.
• [260] K-RAS transformation in prostate epithelial cell overcomes H2O2-induced apoptosis via upregulation of gamma-glutamyltransferase-2. Toxicol In Vitro. 2012 Apr;26(3):429-34. doi: 10.1016/j.tiv.2012.01.013. Epub 2012 Jan 17.
• [261] Nitric oxide inhibits execution of apoptosis at two distinct ATP-dependent steps upstream and downstream of mitochondrial cytochrome c release. Biochem Biophys Res Commun. 1999 Apr 29;258(1):215-21. doi: 10.1006/bbrc.1999.0491.
• [262] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [263] Under ambient UVA exposure, pefloxacin exhibits both immunomodulatory and genotoxic effects via multiple mechanisms. J Photochem Photobiol B. 2018 Jan;178:593-605. doi: 10.1016/j.jphotobiol.2017.12.014. Epub 2017 Dec 15.
• [264] Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
• [265] In vitro antioxidant and antigenotoxic potentials of 3,5-O-di-galloylquinic acid extracted from Myrtus communis leaves and modulation of cell gene expression by H2O2. J Appl Toxicol. 2012 May;32(5):333-41.
• [266] HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J. 2005 Mar;19(3):476-8. doi: 10.1096/fj.04-2745fje. Epub 2004 Dec 29.
• [267] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [268] Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther. 2003 Sep;2(9):893-900.
• [269] Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med. 2004 Jan;10(1):40-7. doi: 10.1038/nm969. Epub 2003 Dec 14.
• [270] Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
• [271] Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
• [272] Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
• [273] The role of MITF and Mcl-1 proteins in the antiproliferative and proapoptotic effect of ciprofloxacin in amelanotic melanoma cells: In silico and in vitro study. Toxicol In Vitro. 2020 Aug;66:104884. doi: 10.1016/j.tiv.2020.104884. Epub 2020 May 8.
• [274] Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation. Br J Cancer. 2011 Jul 12;105(2):221-30. doi: 10.1038/bjc.2011.229.
• [275] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [276] D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
• [277] Anti-cancer properties of glucosamine-hydrochloride in YD-8 human oral cancer cells: Induction of the caspase-dependent apoptosis and down-regulation of HIF-1. Toxicol In Vitro. 2012 Feb;26(1):42-50. doi: 10.1016/j.tiv.2011.10.005. Epub 2011 Oct 13.
• [278] Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004 Jan;3(1):71-84.
• [279] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [280] Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10.
• [281] The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. doi: 10.1016/j.taap.2020.114915. Epub 2020 Feb 6.
• [282] Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
• [283] Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer. 2011 Apr 12;104(8):1278-87. doi: 10.1038/bjc.2011.84.
• [284] Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer. 2011 Jul 31;10:95. doi: 10.1186/1476-4598-10-95.
• [285] The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
• [286] Melatonin enhances hydrogen peroxide-induced apoptosis in human promyelocytic leukaemia HL-60 cells. Mol Cell Biochem. 2011 Jul;353(1-2):167-76. doi: 10.1007/s11010-011-0783-8. Epub 2011 Mar 23.
• [287] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [288] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [289] Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther. 2002 Jul;1(9):667-77.
• [290] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [291] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [292] Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009 Mar;144(5):667-76. doi: 10.1111/j.1365-2141.2008.07504.x. Epub 2008 Nov 20.
• [293] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [294] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [295] Combination of all-trans retinoic acid and taxol regressed glioblastoma T98G xenografts in nude mice. Apoptosis. 2007 Nov;12(11):2077-87. doi: 10.1007/s10495-007-0116-2. Epub 2007 Aug 16.
• [296] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [297] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [298] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [299] Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
• [300] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [301] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [302] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.